Likelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Rett Syndrome
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Rett Syndrome report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Cannabidiol in Rett Syndrome Drug Details:
Cannabidiol (Epidiolex , Epidyolex) is a phytocannabinoid, one of the active cannabinoid identified within the Cannabis plant accounting for up to 40% of the Cannabis plant’s extract, acts as an anti-epileptic agent. It is formulated as a solution for oral route of administration. Epidiolex is indicated for the treatment of seizures associated with Lennox-gastaut syndrome or dravet syndrome in patients 2 years of age and older and Rett syndrome and also as an adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older or it is also indicated for tuberous sclerosis complex (TSC) in patients 1 year of age and older. Cannabidiol (Epidiolex) is under development for the treatment of electrical status epilepticus of sleep (ESES), anxiety disorders with Tourette syndrome, tuberous sclerosis complex in patients age 1 month to less than 12 months, epilepsy with myoclonic atonic seizures, Lennox-Gastaut syndrome (LGS) Dravet syndrome, schizophrenia, autism spectrum disorder (pervasive developmental disorder), tuberous sclerosis complex, anorexia nervosa, Sturge-Weber syndrome, infantile spasm, tremor in Parkinson’s Disease, heroin use disorder, opioid use disorder, developmental and epileptic encephalopathy, psychosis and Fragile-X syndrome (FXS). It was under development for Rett syndrome and schizophrenia related psychotic disorder. It was also under development for the treatment of blepharospasm, neonatal Hypoxic-Ischemic Encephalopathy.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Cannabidiol LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports